Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS
Continue readingCoverage of Global Pharma Industry News
Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS
Continue readingVyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of
Continue readingThe Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market
Continue reading